3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Fátima Cardoso, Eric P. Winer, A. Costa et al.|Annals of Oncology|2016Cited by 2.1k
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Kornélia Polyák, Charles Y. Lin et al.|Nature|2016Cited by 629
Current Landscape of Immunotherapy in Breast CancerSylvia Adams, Elizabeth A. Mittendorf, Margaret E. Gatti‐Mays et al.|JAMA Oncology|2019Cited by 409
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIAIan E. Krop, Véronique Dièras|Annals of Oncology|2014Cited by 401
Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid TumorsIan E. Krop, Patricia LoRusso|Journal of Clinical Oncology|2012Cited by 314